The use of heterologously expressed drug metabolizing enzymes- state of the art and prospects for the future

Pharmacology and Therapeutics

Volumn 84, Issue 2, 1999, Pages 121-131

  Crespi, Charles L ^a   Miller, Vaughn P ^a  

^a Gentest Corporation   (United States)

Author keywords

Cytochrome P450; Drug interactions; Drug metabolism; Hepatic; Liver

Indexed keywords

BUFURALOL; CISAPRIDE; COMPLEMENTARY DNA; CYTOCHROME P450; DEXTROMETHORPHAN; DICLOFENAC; DRUG METABOLIZING ENZYME; ENZYME INHIBITOR; ERYTHROMYCIN; FLUOXETINE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; MIDAZOLAM; NIFEDIPINE; NORFLUOXETINE; PERHEXILINE; PROPRANOLOL; QUINIDINE; SPARTEINE; TERFENADINE;

CONTROLLED STUDY; DRUG DEVELOPMENT; DRUG INTERACTION; DRUG METABOLISM; DRUG SCREENING; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER; PRIORITY JOURNAL; REVIEW;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; LIVER; PHARMACEUTICAL PREPARATIONS;

EID: 0032866401     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(99)00028-5     Document Type: Review

References (51)

1. 1. Proc Natl Acad Sci USA. 87:1990;4790-4793.
2. Barnes H.J., Arlotto M.P., Waterman M.R. Expression and enzymatic activity of recombinant cytochrome P450 17(alpha)-hydroxylase in Escherichia coli. Proc Natl Acad Sci USA. 88:1991;5597-5601.
3. Battula N., Sagara J., Gelboin H.V. Expression of P1-450 and P3-450 DNA coding sequences as enzymatically active cytochromes P-450 in mammalian cells. Proc Natl Acad Sci USA. 84:1987;4073-4077.
4. Burke M.D., Meyer R.T. Differential effects of phenobartitone and 3-methylcholanthrene induction on the hepatic microsomal metabolism and cytochrome P-450-binding of phenoxazone and a homologous series of its O-alkoxy ethers. Chem Biol Interact. 45:1983;243-258.
5. Buters J.T.M., Korzekwa K.R., Kunze K.L., Omata Y., Hardwick J.P., Gonzalez F.J. cDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus. Drug Metab Dispos. 22:1994;688-692.
6. Chen L., Buters J.T.M., Hardwick J.P., Tamura S., Penman B.W., Gonzalez F.J., Crespi C.L. Coexpression of cytochrome P4502A6 and human NADPH-P450 oxidoreductase in the baculovirus system. Drug Metab Dispos. 25:1997;399-405.
7. Code E.L., Crespi C.L., Penman B.W., Gonzalez F.J., Chang T.K.H., Waxman D.J. Human cytochrome P4502B6. Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos. 25:1997;985-993.
8. Crespi C.L. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Meyer U.A., Testa B. Advances in Drug Research. 1995;179-235 Academic Press, New York.
9. Crespi C.L., Miller V.P. The R144C change of CYP2C9*2 allele alters interaction of the cytochrome P450 with NAPDH:cytochrome P450 oxidoreductase. Pharmacogenetics. 7:1997;203-210.
10. Crespi C.L., Penman B.W., Leakey J.A.E., Arlotto M.P., Stark A., Turner T., Steimel D., Rudo K., Davies R.L., Langenbach R.L. Human cytochrome P450IIA3. cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1 Carcinogenesis. 8:1990;1293-1300.
11. Crespi C.L., Gonzalez F.J., Steimel D.T., Turner T.R., Gelboin H.V., Penman B.W., Langenbach R. A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic cytochrome P4502D6. Carcinogenesis. 12:1991;1197-1201. a.
12. Crespi C.L., Gonzalez F.J., Steimel D.T., Turner T.R., Gelboin H.V., Penman B.W., Langenbach R. A metabolically competent cell line expressing five cDNAs encoding procarcinogen-activating enzymes. Applications to mutagenicity testing Chem Res Toxicol. 4:1991;566-572. b.
13. Crespi C.L., Miller V.P., Penman B.W. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem. 248:1997;188-190.
14. Dai Y., Rashba-Step J., Cederbaum A.I. Stable expression of human cytochrome P4502E1 in HepG2 cells. characterization of catalytic properties and production of reactive oxygen species Biochemistry. 32:1993;6928-6937.
15. Ding S., Yao D., Burchell B., Wolf C.R., Friedberg T. High levels of recombinant CYP3A4 expression in Chinese hamster ovary cells are modulated by co-expression of human P450 reductase and hemin supplementation. Arch Biochem Biophys. 348:1997;403-410.
16. 1. Proc Natl Acad Sci USA. 85:1988;5769-5773.
17. Dong J., Porter T.D. Co-expression of mammalian cytochrome P450 and reductase in Escherichia coli. Arch Biochem Biophys. 327:1996;254-259.
18. Furuya H., Fernandez-Salguero P., Gregory W., Taber H., Steward A., Gonzalez F.J., Idle J.R. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics. 5:1995;389-392.
19. Gonzalez F.J., Korzekwa K.R. Cytochromes P450 expression systems. Annu Rev Pharmacol Toxicol. 35:1995;369-390.
20. Gonzalez F.J., Skoda R.C., Kimura S., Umeno M., Zanger U.M., Nebert D.W., Gelboin H.V., Hardwick J.P., Meyer U.A. Characterization of the common genetic defect in human deficient for debrisoquine metabolism. Nature. 331:1988;442-446.
21. Gonzalez F.J., Kimura S., Tamura S., Gelboin H.V. Expression of mammalian cytochrome P450 using baculovirus. Methods Enzymol. 206:1991;93-99.
22. Haining R.L., Hunter A.P., Veronese M.E., Trager W.F., Rettie A.E. Allelic variants of human cytochrome P450 2C9. Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of wild-type and I359L mutant forms Arch Biochem Biophys. 333:1996;447-458.
23. Houston J.B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol. 47:1994;1469-1479.
24. Ioannides C. Part II. Cytochrome P450 families/subfamilies. Ioannides C. Cytochromes P450. Metabolic and Toxicological Aspects:1996;77-300 CRC Press, New York.
25. Iwata H., Fujita K., Kushida H., Suzuki A., Konno Y., Nakamura K., Fujino A., Kamataki T. High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochem Pharmacol. 55:1998;1315-1325.
26. Korzekwa K.R., Krishnamachury N., Shou M., Ogai A., Parise R.A., Rettie A.E., Gonzalez F.J., Tracy T.S. Evaluation of atypical cytochrome P450 kinetics with two-substrate models. Evidence that multiple substrates can simultaneously bind to the cytochrome P450 active sites Biochemistry. 37:1998;4137-4147.
27. Lee C.A., Kadwell S.H., Kost T.A., Serabjit-Singh C.J. CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4. Arch Biochem Biophys. 319:1995;157-167.
28. Murray M. P450 enzymes. Inhibition mechanism, genetic regulation and effects of liver disease. Clin Pharmacokinet. 23:1992;132-146.
29. Nelson D.R., Koymans L., Kamataki T., Stegeman J.J., Feyereisen R., Waxman D.J., Waterman M.R., Gotoh O., Coon M.J., Estabrook R.W., Gunsalus I.C., Nebert D.W. P450 superfamily. update on new sequences, gene mapping, accession numbers and nomenclature Pharmacogenetics. 6:1996;1-42.
30. Obach R.S. Nonspecific binding to microsomes. impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine and propranalol Drug Metab Dispos. 25:1997;1359-1369.
31. Oeda K., Sakati T., Ohkawa H. Expression of rat liver cytochrome P450MC in Saccharomyces cerevisiae. DNA Cell Biol. 4:1985;167-175.
32. Palamanda J.R., Favreau L., Lin C.-C., Nomeir A.A. Validation of a rapid microtiter plate assay to conduct cytochrome P450 2D6 enzyme inhibition studies. Drug Discov Today. 3:1998;466-470.
33. 5. Eur J Biochem. 207:1992;109-116.
34. Pritchard M.P., Glancey M.J., Blake J.A.R., Gilham D.E., Burchell B., Wolf R.C., Friedberg T. Functional expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli. Pharmacogenetics. 8:1998;33-42.
35. Rendic S., Di Carlo F.J. Human cytochrome P450 enzymes. a status report summarizing their reactions, substrates, inducers and inhibitors Drug Metab Rev. 29:1997;413-580.
36. Rettie A.E., Wienkers L.C., Gonzalez F.J., Trager W.F., Korzekwa K.R. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. 4:1994;39-42.
37. 14C]-dextromethorphan. Anal Biochem. 219:1994;309-320.
38. Rodrigues A.D., Kukulka M.J., Roberts E.M., Ouellet D., Rodgers T.R. O-Methyl C-14)naproxen O-demethylase activity in human liver microsomes - evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Drug Metab Disp. 24:1996;126-136.
39. 14C]phenacetin O-deethylase activity in human liver microsomes. Drug Metab Disp. 25:1997;1097-1100.
40. Shah V.P., Midha K.K., Dighe S., McGilveray I.J., Skelly J.P., Yacobi A., Layloff T., Viswanathan C.T., Cook C.E., McDowall R.D., Pittman K.A., Spector S. Analytical methods validation. bioavailability, bioequivalence and pharmacokinetic studies Pharm Res. 9:1992;588-592.
41. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals - studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 270:1994;414-423.
42. Spatzenegger M., Jaeger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev. 27:1995;397-417.
43. Sullivan-Klose T.H., Ghanayem B.I., Bell D.A., Zhang Z.-Y., Kaminsky L.S., Shenfield G.M., Miners J.O., Birkett D.J., Goldstein J.A. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 6:1996;341-349.
44. Tamura S., Korzekwa K.R., Kimura S., Gelboin H.V., Gonzalez F.J. Baculovirus-mediated expression and functional characterization of human NADPH-P450 oxidoreductase. Arch Biochem Biophys. 293:1992;219-223.
45. Venkatakrishnan K., von Molke L.L., Greenblatt D.J. Relative quantities of catalytically active CYP2C9 and 2C19 in human liver microsomes. Applications of the relative activity factor approach J Pharm Sci. 87:1998;845-853.
46. White I.N.H. A continuous assay for cytochrome P-450-dependent mixed function oxidases using 3-cyano-7-ethoxycoumarin. Anal Biochem. 172:1988;304-310.
47. Wrighton S.A., Stevens J.C., Becker G.W., VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19. correlation between 2C19 and S-mephenytoin 4′-hydroxylase Arch Biochem Biophys. 306:1993;240-245.
48. Wynalda M.A., Wienkers L.C. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos. 25:1997;1211-1214.
49. Yamazaki H., Shimada T. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Biochem Pharmacol. 54:1997;1195-1203.
50. 5. J Biol Chem. 271:1996;27438-27444.
51. Yang T.J., Krausz K.W., Shou M., Yang S.K., Buters J.T.M., Gonzalez F.J., Gelboin H.V. Inhibitory monoclonal antibody to human cytochrome P450 2B6. Biochem Pharmacol. 55:1998;1633-1640.